Evidence map›Paper›PMID 37211586›Full record

ArticlePurinergic signalling2024

Purinergic P2X

Ximeng He, Zhichao Zhou

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Ximeng HeSchool of Acupuncture and Tuina/International Joint Research Centre On Purinergic Signalling, Chengdu University of Traditional Chinese Medicine, 37 Shi-Er-Qiao Road, Chengdu, 610075, China.
Zhichao ZhouDivision of Cardiology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, 17176, Stockholm, Sweden. zhichao.zhou@ki.se.ORCID 0000-0002-5107-6529
Chengdu University of Traditional Chinese Medicine · CNKarolinska University Hospital · SE

Funding

EFSD/Novo Nordisk Foundation Future Leaders Awards NNF22SA0081227Swedish Heart and Lung Foundation 20200326 and 20220264
6 · The paper itself

Abstract

Heart failure is associated with multiple mechanisms, including sympatho-excitation, and is one of the leading causes of death worldwide. Enhanced carotid body chemoreflex function is strongly related to excessive sympathetic nerve activity and sleep-disordered breathing in heart failure. How to reduce the excitability of the carotid body is still scientifically challenging. Both clinical and experimental evidence have suggested that targeting purinergic receptors is of great potential to combat heart failure. In a recent study, Lataro et al. (Lataro et al. in Nat Commun 14:1725, 5) demonstrated that targeting purinergic P2X

Indexed as

Carotid BodyHeart FailureAnimalsMaleNeuronsRatsReceptors, Purinergic P2XReceptors, Purinergic P2X2Receptors, Purinergic P2X3Sympathetic Nervous SystemReceptors, Purinergic P2XReceptors, Purinergic P2X2Receptors, Purinergic P2X3Carotid bodyHeart failurePurinergic P2X3 receptors

Identifiers

PMID37211586
PMCPMC10828460
OpenAlexW4377194441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.